We are proud to announce that PhenoPath is now a Quest Diagnostics Company.
Identifies: The HER2 gene product, which is overexpressed, almost always as a consequence of HER2 gene amplification, in a subset of breast cancers, gastric adenocarcinomas, and other tumors. It is a prognostic and predictive marker, and the target of trastuzumab and other HER2 targeted therapies. Subcellular Localization: Membranous
Disease State: Breast Cancer
CPT Code(s): 88360 (reference only; CPTs may vary)
Turnaround Time: Within 1-2 business days of receipt
Schedule: Monday - Friday
• Formalin-fixed, paraffin-embedded (FFPE) tissue block or cell block - OR - • 1 unstained slide for each test requested plus 3-4 additional unstained slides cut at 4µm